652 related articles for article (PubMed ID: 24837362)
21. Treating menopausal symptoms with a tissue-selective estrogen complex.
Levine JP
Gend Med; 2011 Apr; 8(2):57-68. PubMed ID: 21536225
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the efficacy and safety of bazedoxifene/conjugated estrogens for secondary outcomes including vasomotor symptoms in postmenopausal women by years since menopause in the Selective estrogens, Menopause and Response to Therapy (SMART) trials.
Pinkerton JV; Abraham L; Bushmakin AG; Cappelleri JC; Racketa J; Shi H; Chines AA; Mirkin S
J Womens Health (Larchmt); 2014 Jan; 23(1):18-28. PubMed ID: 24206058
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile.
Lobo RA; Pinkerton JV; Gass MLS; Dorin MH; Ronkin S; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1025-1038. PubMed ID: 19635615
[TBL] [Abstract][Full Text] [Related]
24. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial.
Pinkerton JV; Utian WH; Constantine GD; Olivier S; Pickar JH
Menopause; 2009; 16(6):1116-24. PubMed ID: 19546826
[TBL] [Abstract][Full Text] [Related]
25. Bazedoxifene and Conjugated Equine Estrogen: A Combination Product for the Management of Vasomotor Symptoms and Osteoporosis Prevention Associated with Menopause.
Umland EM; Karel L; Santoro N
Pharmacotherapy; 2016 May; 36(5):548-61. PubMed ID: 27027527
[TBL] [Abstract][Full Text] [Related]
26. Advances in menopausal therapy: the tissue-selective estrogen complex.
Moore A
J Am Assoc Nurse Pract; 2013 Mar; 25(3):126-33. PubMed ID: 24218199
[TBL] [Abstract][Full Text] [Related]
27. The evolving role of oral hormonal therapies and review of conjugated estrogens/bazedoxifene for the management of menopausal symptoms.
Parish SJ; Gillespie JA
Postgrad Med; 2017 Apr; 129(3):340-351. PubMed ID: 28132583
[TBL] [Abstract][Full Text] [Related]
28. The tissue selective estrogen complex: a novel approach to the treatment of menopausal symptoms.
Kagan R
J Womens Health (Larchmt); 2012 Sep; 21(9):975-81. PubMed ID: 22759213
[TBL] [Abstract][Full Text] [Related]
29. Changes in bone mineral density are correlated with bone markers and reductions in hot flush severity in postmenopausal women treated with bazedoxifene/conjugated estrogens.
Gallagher JC; Shi H; Mirkin S; Chines AA
Menopause; 2013 Nov; 20(11):1126-32. PubMed ID: 23632659
[TBL] [Abstract][Full Text] [Related]
30. Bazedoxifene + conjugated estrogens in HT for the prevention of osteoporosis and treatment of vasomotor symptoms associated with the menopause.
Tella SH; Gallagher JC
Expert Opin Pharmacother; 2013 Dec; 14(17):2407-20. PubMed ID: 24093499
[TBL] [Abstract][Full Text] [Related]
31. Conjugated estrogens combined with bazedoxifene: the first approved tissue selective estrogen complex therapy.
Sharifi M; Lewiecki EM
Expert Rev Clin Pharmacol; 2014 May; 7(3):281-91. PubMed ID: 24580081
[TBL] [Abstract][Full Text] [Related]
32. Conjugated estrogen/bazedoxifene tablets for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.
Mirkin S; Komm B; Pickar JH
Womens Health (Lond); 2014 Mar; 10(2):135-46. PubMed ID: 24601804
[TBL] [Abstract][Full Text] [Related]
33. Selective estrogen modulators in menopause.
Gambacciani M
Minerva Ginecol; 2013 Dec; 65(6):621-30. PubMed ID: 24346250
[TBL] [Abstract][Full Text] [Related]
34. Conjugated estrogens and bazedoxifene in minority populations: pooled analysis of four phase 3 trials.
Pinkerton JV; Pickar JH; Ryan KA; Yu CR; Mirkin S; Komm BS
Menopause; 2016 Jun; 23(6):611-20. PubMed ID: 27163519
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women.
Lindsay R; Gallagher JC; Kagan R; Pickar JH; Constantine G
Fertil Steril; 2009 Sep; 92(3):1045-1052. PubMed ID: 19635616
[TBL] [Abstract][Full Text] [Related]
36. Most bothersome symptom in women with genitourinary syndrome of menopause as a moderator of treatment effects.
Pinkerton JV; Bushmakin AG; Abraham L; Cappelleri JC; Komm BS
Menopause; 2016 Oct; 23(10):1092-101. PubMed ID: 27404026
[TBL] [Abstract][Full Text] [Related]
37. Clinical effects of selective estrogen receptor modulators on vulvar and vaginal atrophy.
Pinkerton JV; Stanczyk FZ
Menopause; 2014 Mar; 21(3):309-19. PubMed ID: 23777900
[TBL] [Abstract][Full Text] [Related]
38. Effects of conjugated estrogens/bazedoxifene on lipid and coagulation variables: a randomized placebo- and active-controlled trial.
Skouby SO; Pan K; Thompson JR; Komm BS; Mirkin S
Menopause; 2015 Jun; 22(6):640-9. PubMed ID: 25405570
[TBL] [Abstract][Full Text] [Related]
39. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial.
Pinkerton JV; Harvey JA; Lindsay R; Pan K; Chines AA; Mirkin S; Archer DF;
J Clin Endocrinol Metab; 2014 Feb; 99(2):E189-98. PubMed ID: 24438370
[TBL] [Abstract][Full Text] [Related]
40. Bazedoxifene when paired with conjugated estrogens is a new paradigm for treatment of postmenopausal women.
Pinkerton JV; Stovall DW
Expert Opin Investig Drugs; 2010 Dec; 19(12):1613-21. PubMed ID: 21073353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
